Arvaya Healthcare is acquiring 100% of Sushodha Institute of Gastroenterology for ₹15.49 crore via share issuance. The company also plans a ₹210 crore rights issue for growth and has approved relocating its registered office. The acquisition aims to boost synergies and expand services.
Arvaya Healthcare Acquires Specialty Hospital, Plans Major Fundraising
Arvaya Healthcare will acquire 100% of Sushodha Institute of Gastroenterology Private Limited (SIGPL) for ₹15.49 crore. The deal involves issuing 38.71 lakh shares of Arvaya Healthcare at ₹40 each. The company also plans a rights issue of up to ₹210 crore.
Reader Takeaway: Acquisition expands specialty services; rights issue fuels growth capital.
What just happened
Arvaya Healthcare's board has approved the acquisition of Sushodha Institute of Gastroenterology Private Limited, a move aimed at creating business synergies and expanding its hospital and diagnostic network. The purchase consideration of ₹15.49 crore will be paid through a preferential allotment of 38.71 lakh equity shares.
Additionally, the board has approved a rights issue to raise up to ₹210 crore. A committee has been formed to manage the details of this fundraising exercise.
Why this matters
The acquisition of SIGPL, a profitable entity, is expected to enhance Arvaya Healthcare's revenue streams and strengthen its balance sheet. The significant rights issue indicates a plan for substantial expansion or investment, which could drive future growth. The relocation of the registered office from Assam to Maharashtra also signifies a strategic shift in its operational base.
The backstory
SIGPL has demonstrated consistent growth in its turnover over the past three financial years, with figures projected to reach ₹8.99 crore by FY26. This acquisition aligns with Arvaya Healthcare's strategy to integrate offerings and expand its market presence in gastroenterology services.
What changes now
The company will proceed with the share issuance for the acquisition and initiate the process for the rights issue. Shareholders will need to approve these corporate actions via a postal ballot. The relocation of the registered office is also a key operational change.
Risks to watch
Execution risks associated with integrating SIGPL and the terms and subscription success of the ₹210 crore rights issue are key points for investors. Shareholder approval and regulatory clearances for various corporate actions need to be monitored.
Peer comparison
While specific peer data isn't provided in the filing, the acquisition targets expansion in the healthcare services sector, specifically gastroenterology, a growing segment within the broader Indian healthcare market. Companies focusing on specialty treatments and diagnostic services often see investor interest.
Context metrics (time-bound)
- Acquisition Consideration: ₹15.49 crore (discharged via 38.71 lakh shares at ₹40/share).
- Rights Issue Size: Up to ₹210 crore.
- SIGPL Turnover: ₹6.36 crore (2023-24), ₹7.78 crore (2024-25 est.), ₹8.99 crore (2025-26 est.).
- Target Completion: Within 12 months (for acquisition).
What to track next
Investors should closely follow the timeline for shareholder approvals via postal ballot, the finalization of the rights issue terms, and the completion of the SIGPL acquisition. Updates on the registered office relocation and any new management appointments will also be crucial.